drugset / Trial / NCT02634320

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

NCT02634320

Phase 4 Completed 51 enrolled Alkermes, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).

Timeline

Start
2015-12
Primary completion
2017-07-11
Completion
2017-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Lauroxil Small molecule 441 mg Intramuscular
Subject Aripiprazole Lauroxil Small molecule 662 mg Intramuscular
Subject Aripiprazole Lauroxil Small molecule 882 mg Intramuscular

Indications